This invention is directed to bicyclic and tricyclic compounds which are
selective antagonists for NPY (Y5) receptors. The invention provides a
pharmaceutical composition comprising a therapeutically effective amount
of a compound of the invention and a pharmaceutically acceptable carrier.
This invention provides a pharmaceutical composition made by combining a
therapeutically effective amount of a compound of this invention and a
pharmaceutically acceptable carrier. The invention provides a process for
making a pharmaceutical composition comprising combining a
therapeutically effective amount of a compound of the invention and a
pharmaceutically acceptable carrier. This invention further provides the
use of a compound of the invention for the preparation of a
pharmaceutical composition for treating an abnormality, wherein the
abnormality is alleviated by decreasing the activity of a human Y5
receptor.
